Biotech Values

[DewDiligence]

[OT]—Thanks for mentioning the book; I’ll check it out.

MON has been a badly managed company, IMO, but it's the best play I know of on the ag component of The Global Demographic Tailwind. So I try to ignore the small stuff and focus on the landscape 5-10 years out. Unless the company screws up far worse than it ever has, I can't see why MON shouldn’t be a $100B company in due course. Regards, Dew